{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-269399","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.585735+00:00","generated_at":"2026-06-09T00:50:10.578910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track","bullets":["Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.","Cash, equivalents and marketable securities totaled $619.3M as of Sept 30, 2023.","R&D expenses fell to $18.6M from $21.3M, driven by NUV-422 termination and headcount reduction.","Phase 1 monotherapy and Phase 1b combo studies of NUV-868 (BETi) ongoing in advanced solid tumors.","IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-269399","json":"https://secwatch.observer/filing/0001193125-23-269399.json","markdown":"https://secwatch.observer/filing/0001193125-23-269399.md","text":"https://secwatch.observer/filing/0001193125-23-269399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/0001193125-23-269399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/d563136d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:50:10.578910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c68bff1ed846c8760fafaa33a8eb412912d07c8e","claim":"Nuvation Bio Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $19.6 million, or $(0.09) per share, EPS $(0.09) per share.","evidence_excerpt":"Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/0001193125-23-269399-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $19.6 million, or $(0.09) per share"},{"label":"EPS","value":"$(0.09) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}